168 related articles for article (PubMed ID: 35456281)
61. [Investigation and analysis of health-related quality of life in myasthenia gravis patients with myasthenia gravis quality of life-15 Chinese version].
Miao XH; Lian ZY; Liu J; Chen HX; Shi ZY; Zhou HY; Yang R
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):514-520. PubMed ID: 29930422
[TBL] [Abstract][Full Text] [Related]
62. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.
Barnett C; Bril V; Bayoumi AM
Eur J Neurol; 2019 Mar; 26(3):452-459. PubMed ID: 30315714
[TBL] [Abstract][Full Text] [Related]
63. Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
Funke M; Eveslage M; Zschüntzsch J; Hagenacker T; Ruck T; Schubert C; Schroeter M; Meisel A; Wiendl H; Hoffmann S; Lünemann JD
J Neurol; 2024 Jun; ():. PubMed ID: 38871821
[TBL] [Abstract][Full Text] [Related]
64. Preliminary Findings of a Dedicated Ocular Myasthenia Gravis Rating Scale: The OMGRate.
Wong SH; Eggenberger E; Cornblath W; Xhepa A; Miranda E; Lee H; Burke A; Barnett C
Neuroophthalmology; 2020 Jun; 44(3):148-156. PubMed ID: 32395166
[TBL] [Abstract][Full Text] [Related]
65. Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease.
Stojanov A; Milošević V; Đorđević G; Stojanov J
Neurologist; 2019 Jul; 24(4):115-120. PubMed ID: 31246720
[TBL] [Abstract][Full Text] [Related]
66. The MG Composite: A valid and reliable outcome measure for myasthenia gravis.
Burns TM; Conaway M; Sanders DB;
Neurology; 2010 May; 74(18):1434-40. PubMed ID: 20439845
[TBL] [Abstract][Full Text] [Related]
67. Effects of intravascular photobiomodulation on motor deficits and brain perfusion images in intractable myasthenia gravis: A case report.
Lan CH; Wu YC; Chiang CC; Chang ST
World J Clin Cases; 2022 Aug; 10(24):8718-8727. PubMed ID: 36157830
[TBL] [Abstract][Full Text] [Related]
68. Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials.
Weng S; Li J; Chen B; He L; Zhong Z; Huang L; Zhang S; Liu F; Jiang Q
Trials; 2022 Apr; 23(1):365. PubMed ID: 35477531
[TBL] [Abstract][Full Text] [Related]
69. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
70. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
Front Immunol; 2022; 13():839075. PubMed ID: 35371086
[TBL] [Abstract][Full Text] [Related]
71. Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Chen P; Feng H; Deng J; Luo Y; Qiu L; Ou C; Liu W
J Neurol; 2016 Jan; 263(1):83-8. PubMed ID: 26514837
[TBL] [Abstract][Full Text] [Related]
72. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).
Basta IZ; Pekmezović TD; Perić SZ; Kisić-Tepavčević DB; Rakočević-Stojanović VM; Stević ZD; Lavrnić DV
Neurol Sci; 2012 Dec; 33(6):1375-81. PubMed ID: 22875151
[TBL] [Abstract][Full Text] [Related]
73. Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life.
Boscoe AN; Xin H; LʼItalien GJ; Harris LA; Cutter GR
J Clin Neuromuscul Dis; 2019 Jun; 20(4):173-181. PubMed ID: 31135620
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study.
Li J; Weng S; Lin S; Huang L; Yang X; Liang B; Lu J; Jiang Q
Front Neurol; 2021; 12():782980. PubMed ID: 35002931
[No Abstract] [Full Text] [Related]
75. Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.
Vrinten C; Lipka AF; van Zwet EW; Schimmel KJ; Cornel MC; Kuijpers MR; Hekster YA; Weinreich SS; Verschuuren JJ
BMJ Open; 2015 Jul; 5(7):e007863. PubMed ID: 26185179
[TBL] [Abstract][Full Text] [Related]
76. [Pharmacological treatment compliance and a description of its associated factors in patients with myasthenia gravis].
Idiaquez JF; Gonzalez S; Lasso-Penafiel J; Barnett C
Rev Neurol; 2018 Jan; 66(1):15-20. PubMed ID: 29251338
[TBL] [Abstract][Full Text] [Related]
77. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
78. Disease-specific measure of quality of life for myasthenia gravis.
Mullins LL; Carpentier MY; Paul RH; Sanders DB;
Muscle Nerve; 2008 Aug; 38(2):947-56. PubMed ID: 18697209
[TBL] [Abstract][Full Text] [Related]
79. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
[TBL] [Abstract][Full Text] [Related]
80. Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items".
Mourão AM; Araújo CM; Barbosa LS; Gomez RS; Burns TM; Lemos SM; Teixeira AL
Arq Neuropsiquiatr; 2013 Dec; 71(12):955-8. PubMed ID: 24347015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
